PATENT CLAIM ANALYSIS

Application Number: 15875532
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "145100"]

Abstract:
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Claim (Index 13):
The method of  claim 9 , wherein the antibody alleviates the immunosuppressive tumor microenvironment.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 86.0
- Lexical Diversity: 1.26316
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14227733', '15649373', '14547026', '14270750', '14383602']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.728672159933684
- 35 USC 102 Novelty (BERT): 0.5358129509376277
- Combined Prediction Score: 0.7093862390340783
- Mean Citation Score: 356.9909
- Max Citation Score: 363.25638
- Similarity Product: 245.7083063830769

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test